Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Trial in Genotype 2, 3, 4, 5 and 6 Hepatitis C-Infected Subjects to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 Following 7 Days Once Daily Dosing as Monotherapy.

Next Previous
Trial Profile

An Open-Label Trial in Genotype 2, 3, 4, 5 and 6 Hepatitis C-Infected Subjects to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 Following 7 Days Once Daily Dosing as Monotherapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Simeprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms OPERA-2
  • Sponsors Janssen R&D Ireland

Most Recent Events

  • 01 Oct 2010 According to a Medivir media release, the results of this trial will be presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
  • 27 Apr 2010 Additional trial location (Ireland) identified as reported by ClinicalTrials.gov.
  • 12 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top